Celgene-CELG Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG

CELG 108.24

0.0%

Nov 22 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (240)	1/21/1999 8:53:00 AM
From: Biomaven	Read Replies (2) of 804

News on the financing - looks to me like good terms - convertible at a slight premium to the current price. Peter News Alert from PR Newswire via Quote.com Topic: (NASDAQ:CELG) Celgene Corp, Quote.com News Item #8833440 Headline: Celgene Announces New Financing ====================================================================== WARREN, N.J., Jan. 21 /PRNewswire/ -- Celgene Corporation (NASDAQ:CELG) announced today that it had placed $15 million principal amount of convertible notes with John Hancock Mutual Life Insurance Company and several of its affiliates. The notes are convertible beginning January, 2000 into Celgene Common Stock at $18.00 per share. Warburg Dillon Read LLC acted as agent in connection with the financing. The Company will use the proceeds for general corporate purposes. Celgene Corporation, headquartered in Warren, NJ, is engaged in the development of pharmaceuticals and agrochemicals. SOURCE Celgene Corporation -0- 01/21/99 /CONTACT: Sol J. Barer, Ph.D., President & COO of Celgene Corporation, 732-271-4153/

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next